Key facts
- CoreTissue BioEngineering’s last known valuation is $20.7M (Feb 2023).
- It has raised $8.0M; the latest was Later Stage VC ($3.9M) in Nov 2025.
- Notable investors include J-Startup, CONNECT(San Diego), Mitsui Sumitomo Insurance Co., AXA Life Insurance, Japan Science And Technology Agency — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for CoreTissue BioEngineering
- ·The full record, as it builds
Funding rounds
No funding rounds for CoreTissue BioEngineering are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CoreTissue BioEngineering
Developer of implantable artificial ligaments designed for anterior cruciate ligament reconstruction. The company develops artificial ligaments that are used for the reconstruction of anterior knee cruciate ligaments using decellularized tissue that removes cellular components from biological tissues and then transplants them into the body, enabling patients to have a reconstruction of the anterior knee cruciate ligaments and lead a healthy lifestyle.
- Sector
- Healthcare
- HQ
- Yokohama, Japan
- Founded
- 2016
- Employees
- 25
- Website
- coretissue.com/
- Ownership
- Privately Held (backing)
CoreTissue BioEngineering doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CoreTissue BioEngineering shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CoreTissue BioEngineering in its N-PORT filings yet. We sweep new filings monthly.